BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
Accessnewswireยท2025-10-21 07:05
Core Insights - BioNxt Solutions Inc. has launched a large-mass animal bioequivalence study for its lead product, BNT23001, which is a proprietary sublingual Cladribine formulation aimed at treating multiple sclerosis [1] Group 1: Product Development - The study is the final animal study needed to establish dosing parameters for the upcoming human comparative bioequivalence study planned for early 2026 [1]